ArticleHeliyon2025
Overexpressed Wnt-7a acts as a potential antitumor immune modulator and predicts poor prognosis in HNSCC.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor (ICI) has become the first-line treatment of advanced head and neck squamous cell carcinoma (HNSCC), which has a relatively poor clinical prognosis and high mortality. However, only a proportion of patients respond well to ICI therapy. Identifying reliable predictive markers and potential targets to enhance the efficacy of ICI is of great importance. In this study, we systematically screened potential genes related to poor prognosis in HNSCC and Wnt-7a was selected based on results from multiple databases. Wnt-7a was overexpressed in HNSCC tissues and was associated with shorter overall survival. Human tissue samples and further bioinformatic analysis showed that Wnt-7a may be expressed in T cells and inhibited the infiltration and function of cytotoxic T cell response, both directly and indirectly through decrease the infiltration of Th1, Th17 cells and increasing the infiltration of Tregs. Genes that can directly interact with Wnt-7a were also identified. Surprisingly, 8 out of 9 genes identified were found to participate in the modulation of anti-tumor immunity. In addition, our study suggested that Wnt-7a, as a canonical Wnt ligand, could exert its function via regulating Wnt signaling and related mechanisms. Taken together, these results strongly support that Wnt-7a is a strong predictor of prognosis and ICI efficacy, and could be a promising potential target for enhancing the therapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.